AAV gene-therapy manufacturing capacity remains the rate-limit on commercial uptake

Reading the signal

AAV (adeno-associated virus) is the leading delivery vector for in vivo gene therapy. Approved AAV gene therapies in 2026 cover spinal muscular atrophy, hemophilia A and B, retinal dystrophy, beta-thalassemia and sickle cell disease, and muscular dystrophies, with multiple late-stage programs in development.

The manufacturing constraint operates across the lifecycle:

• Vector production capacity is concentrated across a small number of GMP facilities. The lead time from process development to clinical and commercial supply is measured in years, not quarters
• Cost of goods at scale remains high, particularly for high-dose indications that require larger vector quantities per patient
• Yield improvements through producer-cell-line and process intensification are real but incremental

Several specific commercial situations have surfaced in the past two years:

• Approved gene therapies that cannot fully meet eligible-patient demand at launch and require allocation frameworks
• Late-stage programs delaying pivotal trial enrolment to align with confirmatory commercial supply timing
• Sponsor capital-allocation decisions diverting clinical-stage investment toward facility build rather than additional clinical programs

Commercial implications

For sponsors of AAV gene therapies in development or in early commercial life:

1. Commercial supply needs to be the launch model, not a launch-readiness milestone. Sponsors that approach AAV launches with conventional drug-launch supply assumptions face the patient-allocation problem within months of approval.
2. Cost of goods is a strategic commercial axis, not a finance-team metric. A two-fold improvement in cost of goods at scale is the difference between a commercial gene therapy that can support standard payer arrangements and one that requires bespoke financing structures.
3. The contract-manufacturer relationship is more strategic than for conventional therapies. Multi-source CDMO strategies are now standard; single-source dependencies are emerging as a commercial risk that boards are tracking.

What we are watching

• Approved gene therapy commercial uptake curves and the relationship between approval timing and manufacturing readiness
• Capacity build announcements across the major CDMOs and how those landings reshape the late-stage pipeline supply picture
• Process-intensification publications and yield-improvement data, particularly for high-dose indications where the supply bottleneck is most acute